Greenwich LifeSciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Snehal Patel
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 20.2% |
| CEO tenure | 14.8yrs |
| CEO ownership | 42.1% |
| Management average tenure | no data |
| Board average tenure | 14.8yrs |
Recent management updates
Recent updates
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Aug 22
Greenwich LifeSciences: Trying To Move A Needle That Doesn't Like To Budge
Jun 26Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$10m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | US$3m | US$557k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$2m | US$506k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$450k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$999k | US$115k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$1m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$139k | n/a | -US$3m |
Compensation vs Market: Snehal's total compensation ($USD2.75M) is above average for companies of similar size in the US market ($USD1.44M).
Compensation vs Earnings: Snehal's compensation has increased whilst the company is unprofitable.
CEO
Snehal Patel (61 yo)
14.8yrs
Tenure
US$2,750,029
Compensation
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 14.8yrs | US$2.75m | 42.12% $ 69.3m | |
| Founder & Independent Director | 18.3yrs | US$65.64k | 2.38% $ 3.9m | |
| Chief Medical Officer & Director | 5.3yrs | no data | 0.69% $ 1.1m | |
| Independent Chairman of the Board | 15.8yrs | US$98.39k | 4.72% $ 7.8m | |
| Independent Director | 5.3yrs | US$65.64k | 3.02% $ 5.0m |
14.8yrs
Average Tenure
74yo
Average Age
Experienced Board: GLSI's board of directors are seasoned and experienced ( 14.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Greenwich LifeSciences, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |